Comparative Pharmacology
Head-to-head clinical analysis: MAXAQUIN versus OFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAQUIN versus OFLOXACIN.
MAXAQUIN vs OFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
400 mg orally or intravenously every 12 hours for 7-14 days; for uncomplicated gonorrhea, 400 mg as a single oral dose.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOfloxacin + Digoxin
"Ofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLevofloxacin + Digoxin
"Levofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 4-8 hours in adults with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <20 mL/min).
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Approximately 70-90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 4-8% is excreted in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic